These results indicate that HRD1 suppression even after 6 weeks HFD feeding fully protected mice from developing obesity, hepatic steatosis, and insulin resistance, suggesting that HRD1 is a potential therapeutic target for HFD-induced metabolic disorders. Here, SYVN1 is linked to metabolic disease.